Abpro Corporation(ABP)Earnings, Financials & Key Ratios
ABP•NASDAQ
$0.52
$163525 mkt cap·Price updated Apr 24, 2026
AboutAbpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.Show more
- Revenue$183K+50.0%
- EBITDA-$9M+15.1%
- Net Income-$7M+38.2%
- EPS (Diluted)-23.10+38.4%
- Gross Margin100%
- EBITDA Margin-5081.42%+43.4%
- Operating Margin-5421.31%+43.7%
- Net Margin-3951.91%+58.8%
- Interest Coverage-25.64+95.0%
ABP Key Insights
Abpro Corporation (ABP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Sales declining 35.9% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ABP Price & Volume
Abpro Corporation (ABP) stock price & volume — 10-year historical chart
Loading chart...
ABP Growth Metrics
Abpro Corporation (ABP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-35.85%
3 Years-27.49%
TTM50%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM15.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM58.67%
Return on Capital
10 Years-238.31%
5 Years-348.64%
3 Years-757.38%
Last Year-
ABP Peer Comparison
Abpro Corporation (ABP) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 XNCR | 954.14M | 13.01 | -10.49 | 13.65% | -185.71% | -23.68% | 0.30 | |
 ALXO | 111.98M | 2.09 | -0.81 | -241.09% | 0.15 | |||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare ABP vs Peers
Abpro Corporation (ABP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABP Income Statement
Abpro Corporation (ABP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.69M | 2.2M | 480K | 2.03M | 122K | 183K | 183K |
| Revenue Growth % | - | 30.62% | -78.19% | 322.71% | -93.99% | 50% | 50% |
| Cost of Goods Sold | 1.71M | 1.52M | 8.63M | 9.75M | 0 | 0 | 284K |
| COGS % of Revenue | 101.66% | 69.29% | 1797.29% | 480.73% | - | - | - |
| Gross Profit | -28K▲ 0% | 676K▲ 2514.3% | -8.15M▼ 1305.2% | -7.72M▲ 5.2% | 122K▲ 101.6% | 183K▲ 50.0% | -101K▲ 0% |
| Gross Margin % | -1.66% | 30.71% | -1697.29% | -380.73% | 100% | 100% | -55.19% |
| Gross Profit Growth % | - | 2514.29% | -1305.18% | 5.18% | 101.58% | 50% | - |
| Operating Expenses | 5.35M | 13.03M | 6.83M | 8.96M | 11.87M | 10.1M | 14.59M |
| OpEx % of Revenue | 317.39% | 592.14% | 1422.92% | 441.6% | 9727.87% | 5521.31% | - |
| Selling, General & Admin | 4.22M | 6.93M | 6.83M | 8.96M | 7.6M | 7.12M | 10.73M |
| SG&A % of Revenue | 250.45% | 314.86% | 1422.92% | 441.6% | 6231.15% | 3891.26% | - |
| Research & Development | 1.13M | 6.1M | 8.63M | 9.75M | 4.27M | 2.98M | 881K |
| R&D % of Revenue | 66.94% | 277.28% | 1797.29% | 480.73% | 3496.72% | 1630.05% | - |
| Other Operating Expenses | 0 | 31K | -8.63M | -9.75M | 0 | 0 | 1000K |
| Operating Income | 5.38M▲ 0% | -12.36M▼ 329.9% | -14.98M▼ 21.2% | -16.68M▼ 11.4% | -11.75M▲ 29.6% | -9.92M▲ 15.5% | -14.55M▲ 0% |
| Operating Margin % | 319.05% | -561.43% | -3120.21% | -822.33% | -9627.87% | -5421.31% | -7950.82% |
| Operating Income Growth % | - | -329.85% | -21.2% | -11.4% | 29.6% | 15.54% | - |
| EBITDA | 5.44M | -12.2M | -14.45M | -15.83M | -10.95M | -9.3M | -11.3M |
| EBITDA Margin % | 322.85% | -554.34% | -3011.25% | -780.14% | -8978.69% | -5081.42% | -6174.32% |
| EBITDA Growth % | - | -324.28% | -18.47% | -9.51% | 30.8% | 15.11% | 34.37% |
| D&A (Non-Cash Add-back) | 64K | 156K | 523K | 856K | 792K | 622K | 436K |
| EBIT | -6.04M | -12.36M | -14.98M | -16.64M | -11.68M | -6.84M | -12.6M |
| Net Interest Income | 0 | 0 | -17K | -200K | 40K | -378K | -1.4M |
| Interest Income | 0 | 0 | 0 | 48K | 63K | 9K | 30K |
| Interest Expense | 69K | 0 | 17K | 248K | 23K | 387K | 1.49M |
| Other Income/Expense | -11.48M | 31K | 242K | -200K | 40K | 2.69M | 454K |
| Pretax Income | -6.11M▲ 0% | -12.33M▼ 101.8% | -14.73M▼ 19.5% | -16.89M▼ 14.6% | -11.71M▲ 30.7% | -7.23M▲ 38.2% | -14.1M▲ 0% |
| Pretax Margin % | -362.55% | -560.02% | -3069.79% | -832.18% | -9595.08% | -3951.91% | -7702.19% |
| Income Tax | -595K | 31K | 0 | 330K | 0 | 0 | -57.97K |
| Effective Tax Rate % | 9.74% | -0.25% | 0% | -1.95% | 0% | 0% | 0.41% |
| Net Income | -5.51M▲ 0% | -12.36M▼ 124.1% | -14.73M▼ 19.2% | -17.21M▼ 16.8% | -11.71M▲ 32.0% | -7.23M▲ 38.2% | -14.04M▲ 0% |
| Net Margin % | -327.24% | -561.43% | -3069.79% | -848.45% | -9595.08% | -3951.91% | -7670.49% |
| Net Income Growth % | - | -124.1% | -19.24% | -16.83% | 32% | 38.22% | 15.82% |
| Net Income (Continuing) | -5.51M | -12.36M | -14.73M | -17.21M | -11.71M | -7.23M | -14.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 549K | 549K | 549K | 549K | 549K |
| EPS (Diluted) | -14.10▲ 0% | -31.50▼ 123.4% | -47.70▼ 51.4% | -55.50▼ 16.4% | -37.50▲ 32.4% | -23.10▲ 38.4% | -5.37▲ 0% |
| EPS Growth % | - | -123.4% | -51.43% | -16.35% | 32.43% | 38.4% | 58.67% |
| EPS (Basic) | -14.10 | -31.50 | -47.70 | -55.50 | -37.50 | -23.10 | - |
| Diluted Shares Outstanding | 387.93K | 392.2K | 309.13K | 310.4K | 311.9K | 313.27K | 2.61M |
| Basic Shares Outstanding | 387.93K | 392.2K | 309.13K | 310.4K | 311.9K | 313.27K | 2.61M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
ABP Balance Sheet
Abpro Corporation (ABP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.25M | 14.96M | 6.86M | 9.65M | 1.9M | 3.78M | 1.23M |
| Cash & Short-Term Investments | 7.08M | 14.52M | 6.56M | 7.33M | 723K | 2.85M | 343K |
| Cash Only | 7.08M | 14.52M | 6.56M | 7.33M | 723K | 2.85M | 343K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 108K | 184K | 40K | 2.03M | 88K | 323K | 271K |
| Days Sales Outstanding | 23.39 | 30.51 | 30.42 | 365.18 | 263.28 | 644.24 | 631.77 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 292K | 1.09M | 603K | 611K |
| Total Non-Current Assets | 434K | 2.18M | 1.03M | 2.21M | 1.46M | 885K | 478K |
| Property, Plant & Equipment | 114K | 1.46M | 695K | 1.8M | 1.07M | 455K | 0 |
| Fixed Asset Turnover | 14.78x | 1.51x | 0.69x | 1.13x | 0.11x | 0.40x | 0.79x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 131K | 196K | 186K | 364K | 169K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 320K | 716K | 207K | 207K | 204K | 66K | 552K |
| Total Assets | 7.69M▲ 0% | 17.14M▲ 122.9% | 7.89M▼ 54.0% | 11.85M▲ 50.3% | 3.35M▼ 71.7% | 4.66M▲ 38.9% | 1.7M▲ 0% |
| Asset Turnover | 0.22x | 0.13x | 0.06x | 0.17x | 0.04x | 0.04x | 0.06x |
| Asset Growth % | - | 122.93% | -53.98% | 50.25% | -71.69% | 38.93% | -35.11% |
| Total Current Liabilities | 1.89M | 2.62M | 4.47M | 10.87M | 12.44M | 19.61M | 17.3M |
| Accounts Payable | 76K | 534K | 1.91M | 8.15M | 7.92M | 3.94M | 4.72M |
| Days Payables Outstanding | 16.19 | 127.81 | 80.73 | 305.05 | - | - | 5.99K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 1.74M | 2.87M | 147K |
| Deferred Revenue (Current) | 128K | 99K | 0 | 64K | 0 | 0 | 0 |
| Other Current Liabilities | 1.69M | 1.99M | 0 | 0 | 0 | 80K | 10.11M |
| Current Ratio | 3.84x | 5.71x | 1.53x | 0.89x | 0.15x | 0.19x | 0.19x |
| Quick Ratio | 3.84x | 5.71x | 1.53x | 0.89x | 0.15x | 0.19x | 0.19x |
| Cash Conversion Cycle | - | - | - | - | - | - | -5.35K |
| Total Non-Current Liabilities | 18.14M | 36.99M | 351K | 76.72M | 76.05M | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 351K | 1.12M | 455K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 36.69M | 0 | 75.6M | 75.6M | 0 | 0 |
| Total Liabilities | 20.03M | 39.61M | 4.82M | 87.59M | 88.49M | 19.61M | 17.3M |
| Total Debt | 0 | 0 | 558K | 1.87M | 2.89M | 3.33M | 147K |
| Net Debt | -7.08M | -14.52M | -6M | -5.45M | 2.17M | 478K | -196K |
| Debt / Equity | - | - | 0.18x | - | - | - | -0.01x |
| Debt / EBITDA | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | -1.30x | - | - | - | - | - | 0.02x |
| Interest Coverage | 77.91x | - | -881.00x | -67.28x | -510.70x | -25.64x | -8.45x |
| Total Equity | -12.35M▲ 0% | -22.46M▼ 82.0% | 3.07M▲ 113.7% | -75.73M▼ 2566.1% | -85.14M▼ 12.4% | -14.95M▲ 82.4% | -15.6M▲ 0% |
| Equity Growth % | - | -81.98% | 113.67% | -2566.1% | -12.41% | 82.44% | 55.01% |
| Book Value per Share | -31.82 | -57.28 | 9.93 | -243.99 | -272.96 | -47.71 | -5.97 |
| Total Shareholders' Equity | -12.35M | -22.46M | 2.52M | -76.28M | -85.68M | -15.49M | -16.14M |
| Common Stock | 12K | 14K | 9K | 9K | 9K | 5K | 0 |
| Retained Earnings | -16.62M | -28.95M | -76.65M | -93.86M | -105.57M | -116.1M | -124.63M |
| Treasury Stock | 0 | 0 | -33K | -33K | -33K | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 549K | 549K | 549K | 549K | 549K |
ABP Cash Flow Statement
Abpro Corporation (ABP) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.88M | -9.47M | -10.95M | -8.95M | -7.4M | -9.03M | -9.03M |
| Operating CF Margin % | -289.61% | -430.4% | -2281.67% | -441.2% | -6067.21% | -4934.43% | - |
| Operating CF Growth % | - | -94.12% | -15.61% | 18.26% | 17.31% | -21.99% | -167.8% |
| Net Income | -6.11M | -12.33M | -14.73M | -17.21M | -11.71M | -7.23M | -14.04M |
| Depreciation & Amortization | 64K | 156K | 523K | 856K | 792K | 622K | 436K |
| Stock-Based Compensation | 1.17M | 1.32M | 2.17M | 4.02M | 2.31M | 1.93M | 872K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 725K | 1.02M | 301K | 0 | 0 | -3.03M | 1.98M |
| Working Capital Changes | -733K | 363K | 793K | 3.39M | 1.21M | -1.32M | -2.89M |
| Change in Receivables | 20K | -76K | 40K | -1.99M | 1.94M | -235K | 0 |
| Change in Inventory | -515K | -44K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -268K | 257K | 0 | 6.24M | -743K | -860K | 787K |
| Cash from Investing | -108K | -752K | -87K | -65K | -48K | 0 | -29.61M |
| Capital Expenditures | -108K | -762K | -12K | -65K | -48K | 0 | 0 |
| CapEx % of Revenue | 6.41% | 34.62% | 2.5% | 3.2% | 39.34% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 26K |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 10K | -75K | 0 | 0 | 0 | -29.64M |
| Cash from Financing | 11.93M | 17.67M | -180K | 9.78M | 849K | 11.16M | 42.99M |
| Debt Issued (Net) | 0 | 0 | -180K | -207K | 1.22M | 2.89M | 1.84M |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 | 1000K | 1.87M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -30K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 11.93M | 17.67M | 0 | 0 | -371K | -2.09M | 184.95K |
| Net Change in Cash | 6.94M▲ 0% | 7.45M▲ 7.3% | 6.7M▼ 10.1% | 767K▼ 88.5% | -6.6M▼ 960.6% | 2.13M▲ 132.3% | 329.4K▲ 0% |
| Free Cash Flow | -4.99M▲ 0% | -10.23M▼ 105.2% | -10.96M▼ 7.1% | -9.02M▲ 17.8% | -7.45M▲ 17.4% | -9.03M▼ 21.2% | -13.64M▲ 0% |
| FCF Margin % | -296.02% | -465.02% | -2284.17% | -444.41% | -6106.56% | -4934.43% | -7453.56% |
| FCF Growth % | - | -105.19% | -7.12% | 17.76% | 17.38% | -21.21% | -102.99% |
| FCF per Share | -12.86 | -26.10 | -35.47 | -29.05 | -23.89 | -28.83 | -28.83 |
| FCF Conversion (FCF/Net Income) | 0.89x | 0.77x | 0.74x | 0.52x | 0.63x | 1.25x | 0.97x |
| Interest Paid | 0 | 0 | 30K | 30K | 16K | 1K | 19K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABP Key Ratios
Abpro Corporation (ABP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -479.81% | - | - | - | 85.99% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | 69.49% |
| Gross Margin | 30.71% | -1697.29% | -380.73% | 100% | 100% | -55.19% |
| Net Margin | -561.43% | -3069.79% | -848.45% | -9595.08% | -3951.91% | -7670.49% |
| Debt / Equity | - | 0.18x | - | - | - | -0.01x |
| Interest Coverage | - | -881.00x | -67.28x | -510.70x | -25.64x | -8.45x |
| FCF Conversion | 0.77x | 0.74x | 0.52x | 0.63x | 1.25x | 0.97x |
| Revenue Growth | 30.62% | -78.19% | 322.71% | -93.99% | 50% | 50% |
ABP Frequently Asked Questions
Abpro Corporation (ABP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Abpro Corporation (ABP) reported $0.2M in revenue for fiscal year 2024. This represents a 89% decrease from $1.7M in 2016.
Abpro Corporation (ABP) grew revenue by 50.0% over the past year. This is strong growth.
Abpro Corporation (ABP) reported a net loss of $14.0M for fiscal year 2024.
Dividend & Returns
Abpro Corporation (ABP) had negative free cash flow of $13.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More ABP
Abpro Corporation (ABP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates